EMEA-001849-PIP02-15-M04
Key facts
Invented name |
Bavencio
|
Active substance |
avelumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0546/2021
|
PIP number |
EMEA-001849-PIP02-15-M04
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Merck Healthcare KGaA
Email: service@merckgroup.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|